Xenon Pharmaceuticals Inc. Forecast, price target & analysts
Xenon Pharmaceuticals Inc. Target price 2025 - Analyst rating & recommendation
Xenon Pharmaceuticals Inc. Classifications & Recommendation:
Xenon Pharmaceuticals Inc. Price Target
| Target Price | $56.10 |
| Price | $41.12 |
| Potential |
36.43%
register free of charge
|
| Number of Estimates | 18 |
|
18 Analysts have issued a price target Xenon Pharmaceuticals Inc. 2026 .
The average Xenon Pharmaceuticals Inc. target price is $56.10.
This is
36.43%
register free of charge
$68.25
65.98%
register free of charge
$43.43
5.62%
register free of charge
|
|
| A rating was issued by 25 analysts: 24 Analysts recommend Xenon Pharmaceuticals Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Xenon Pharmaceuticals Inc. stock has an average upside potential 2026 of
36.43%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.00 | 7.68 |
21 Analysts have issued a sales forecast Xenon Pharmaceuticals Inc. 2025 . The average Xenon Pharmaceuticals Inc. sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Xenon Pharmaceuticals Inc. EBITDA forecast 2025. The average Xenon Pharmaceuticals Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
22 Xenon Pharmaceuticals Inc. Analysts have issued a net profit forecast 2025. The average Xenon Pharmaceuticals Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.01 | -4.33 |
| 10.26% | 43.85% | |
| P/E | negative | |
| EV/Sales | 345.74 |
22 Analysts have issued a Xenon Pharmaceuticals Inc. forecast for earnings per share. The average Xenon Pharmaceuticals Inc. EPS is
This results in the following potential growth metrics and future valuations:
Xenon Pharmaceuticals Inc....
Current Xenon Pharmaceuticals Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Chardan Capital |
Locked
➜
Locked
|
Locked | Oct 07 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Sep 02 2025 |
| Wedbush |
Locked
➜
Locked
|
Locked | Aug 12 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Aug 12 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Aug 12 2025 |
| Evercore ISI Group |
Locked
➜
Locked
|
Locked | May 14 2025 |
| Needham |
Locked
➜
Locked
|
Locked | May 13 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Oct 07 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Sep 02 2025 |
|
Locked
Wedbush:
Locked
➜
Locked
|
Aug 12 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Aug 12 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Aug 12 2025 |
|
Locked
Evercore ISI Group:
Locked
➜
Locked
|
May 14 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
May 13 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
